Clincosm LogoSign in Get a demo

LEUK-ALCL: Leukemic Phase of ALCL

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT04908059
Collaborator
(none)
2
Enrollment
1
Location
5.5
Anticipated Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Other
    Official Title:
    Leukemic Phase of ALK+ Anaplastic Lymphoma in Real-life Practice: Experience of a University Clinical Hematology Laboratory
    Actual Study Start Date :
    Jan 27, 2021
    Anticipated Primary Completion Date :
    Jul 13, 2021
    Anticipated Study Completion Date :
    Jul 13, 2021

    Outcome Measures

    Primary Outcome Measures

    1. A retrospective study of the diagnostic description of the leukemic phases of anaplastic lymphoma in real life [Files analysed retrospectively from January 01, 2020 to December 31, 2020 will be examined]]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    9 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients presenting a leukemic phase of anaplastic lymphoma
    Exclusion Criteria:
    • None

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hematology Laboratory - Strasbourg University Hospitals Strasbourg France 67091

    Sponsors and Collaborators

    • University Hospital, Strasbourg, France

    Investigators

    • Study Director: Laurent MAUVIEUX, MD, PhD, Hematology Laboratory - Strasbourg University Hospitals

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Strasbourg, France
    ClinicalTrials.gov Identifier:
    NCT04908059
    Other Study ID Numbers:
    • 8115
    First Posted:
    Jun 1, 2021
    Last Update Posted:
    Jul 8, 2021
    Last Verified:
    May 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Strasbourg, France
    Anaplastic lymphoma
    Leukemic phase
    Additional relevant MeSH terms:
    Lymphoma

    Study Results

    No Results Posted as of Jul 8, 2021